Colloca Luana, Benedetti Fabrizio
Department of Neuroscience, University of Turin Medical School and National Institute of Neuroscience, Corso Raffaello 30, 10125 Turin, Italy.
Curr Opin Anaesthesiol. 2007 Oct;20(5):435-9. doi: 10.1097/ACO.0b013e3282b972fb.
Nocebo hyperalgesia is a phenomenon that is opposite to placebo analgesia and whereby expectation of pain increase plays a crucial role. In recent times, both the neuroanatomical and the neurochemical bases of the nocebo effect and of nocebo-related effects have begun to be explored. Here, we highlight recent advances in our understanding of the neurobiology of the nocebo hyperalgesic effect.
A typical nocebo hyperalgesic response occurs following the administration of an inert substance which the subject believes to be a hyperalgesic agent (negative placebo or nocebo). It has been shown that the subject's negative expectations of pain worsening induce anticipatory anxiety about the impending pain increase and this triggers the activation of cholecystokinin that, in turn, facilitates pain transmission. Accordingly, cholecystokinin antagonists have been found to prevent this anxiety-induced hyperalgesia. Brain-imaging studies have shown that the perceived intensity of a painful stimulus following negative expectations of pain increase is higher than in the absence of negative expectations and this is associated with changes in activation of specific brain regions.
Since pain appears to be amplified by anxiety through the activation of cholecystokininergic systems, new therapeutic strategies, such as new cholecystokinin antagonists, can be envisaged whenever pain has an important anxiety component.
反安慰剂痛觉过敏是一种与安慰剂镇痛相反的现象,其中对疼痛加剧的预期起着关键作用。近年来,反安慰剂效应及相关效应的神经解剖学和神经化学基础已开始得到探索。在此,我们重点介绍在理解反安慰剂痛觉过敏效应的神经生物学方面的最新进展。
在给予受试者认为是痛觉过敏剂(阴性安慰剂或反安慰剂)的惰性物质后,会出现典型的反安慰剂痛觉过敏反应。研究表明,受试者对疼痛恶化的负面预期会引发对即将到来的疼痛加剧的预期性焦虑,进而触发胆囊收缩素的激活,而胆囊收缩素反过来又会促进疼痛传递。因此,已发现胆囊收缩素拮抗剂可预防这种焦虑诱导的痛觉过敏。脑成像研究表明,在对疼痛加剧有负面预期后,疼痛刺激的感知强度高于无负面预期时,这与特定脑区激活的变化有关。
由于疼痛似乎通过胆囊收缩素能系统的激活而被焦虑放大,因此每当疼痛有重要的焦虑成分时,就可以设想新的治疗策略,如新的胆囊收缩素拮抗剂。